Banner

What the impact of 44-week aflibercept data may mean in a real-world setting

Video
Conferences|ASRS Preview

David Brown, MD, highlights his ASRS poster that includes 44-week data for a four-times-higher dose of aflibercept in a real-world setting.

Related Videos
Related Content

World Retina Day: Iveric Bio focusing on GA awareness with More to See campaign

September 24th 2023

(Podcast) Confronting Demodex blepharitis: From rude awakening to FDA-approved solution

August 30th 2023

Foundation Fighting Blindness awards $900,000 to MitoChem Therapeutics to study target and mechanism of action in retinal degeneration disease

September 22nd 2023

EyePod: Detecting ROP earlier in a non-invasive way

July 6th 2023

Macular leakage is important in diabetic eye disease outcomes

September 21st 2023

Disparities remain an obstacle to health equity in eye care

September 20th 2023

World Retina Day: Iveric Bio focusing on GA awareness with More to See campaign

September 24th 2023

(Podcast) Confronting Demodex blepharitis: From rude awakening to FDA-approved solution

August 30th 2023

Foundation Fighting Blindness awards $900,000 to MitoChem Therapeutics to study target and mechanism of action in retinal degeneration disease

September 22nd 2023

EyePod: Detecting ROP earlier in a non-invasive way

July 6th 2023

Macular leakage is important in diabetic eye disease outcomes

September 21st 2023

Disparities remain an obstacle to health equity in eye care

September 20th 2023

World Retina Day: Iveric Bio focusing on GA awareness with More to See campaign

September 24th 2023

(Podcast) Confronting Demodex blepharitis: From rude awakening to FDA-approved solution

August 30th 2023

Foundation Fighting Blindness awards $900,000 to MitoChem Therapeutics to study target and mechanism of action in retinal degeneration disease

September 22nd 2023

EyePod: Detecting ROP earlier in a non-invasive way

July 6th 2023

Macular leakage is important in diabetic eye disease outcomes

September 21st 2023

Disparities remain an obstacle to health equity in eye care

September 20th 2023
© 2023 MJH Life Sciences

All rights reserved.